HIV entry inhibitors and their potential in HIV therapy

✍ Scribed by Keduo Qian; Susan L. Morris-Natschke; Kuo-Hsiung Lee

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 276 KB
• Volume: 29
• Category: Article
• ISSN: 0198-6325
• DOI: 10.1002/med.20138

✦ Synopsis

Abstract

This review discusses recent progress in the development of anti‐HIV agents targeting the viral entry process. The three main classes (attachment inhibitors, co‐receptor binding inhibitors, and fusion inhibitors) are further broken down by specific mechanism of action and structure. Many of these inhibitors are in advanced clinical trials, including the HIV maturation inhibitor bevirimat, from the authors' laboratories. In addition, the CCR5 inhibitor maraviroc has recently been FDA‐approved. Possible roles for these agents in anti‐HIV therapy, including treatment of virus resistant to current drugs, are also discussed. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 2, 369–393, 2009